AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

Park Bo Gum brought fans closer by opening a free chatroom. With no subscriptions, he created a heartfelt space for open communication and connection.

Know about the most common cancers affecting people in India today. Oncology experts discuss prevalent cancers such as breast ...

Millions of new cancer cases are reported every year in the world, including India. As a step to address it, the Indian ...

It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.

APL was once a highly fatal disease, with up to 30% of patients dying early from complications. Traditional treatments often ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

Systemic circulation of chemotherapy drugs leads to off-target side effects, premature drug loss, and limited therapeutic ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

When Melissa Ames started having tooth pain, she went to the dentist. However, it wasn’t just a toothache from a cavity that ...

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.